N-t-Butyl-1H-azepin | 62377-02-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吖庚因类
• 英文名称: N-t-Butyl-1H-azepin
• 英文别名: 1-tert-butyl-1H-azepine；N-tert-butyl-1-aza-cyclohepta-1,3,5-triene；1-tert-Butyl-1H-azepine；1-tert-butylazepine
• CAS: 62377-02-0
• 化学式: C₁₀H₁₅N
• 分子量: 149.236
• InChiKey: RYRKCPBKLDSGCP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  (2R,3R)-1-tert-butyl-2-ethenyl-3-ethynylaziridine 生成 N-t-Butyl-1H-azepin
  参考文献：
  名称：

  MANISSE N.; CHUCHE J., TETRAHEDRON, 1977, 33, NO 18, 960-964

  摘要：

  DOI：

文献信息

• Novel Dosage Form
  申请人：NeuroVive Pharmaceutical AB

  公开号：US20140234414A1

  公开（公告）日：2014-08-21

  There is provided inter alia a pharmaceutical dosage form for oral administration comprising a sanglifehrin as active ingredient in which the sanglifehrin active ingredient is protected from acid degradation in the stomach environment following oral administration.

  提供了一种用于口服的药物剂型，包括桑格利非林作为活性成分，其中桑格利非林活性成分在口服后受到胃酸降解的保护。
• Macrocyclic Compounds and Methods for Their Production
  申请人：Moss Steven James

  公开号：US20140038885A1

  公开（公告）日：2014-02-06

  There is provided inter alia compounds of formula (I): for use in treatment of viral infection or as an immunosuppressant.

  提供了公式（I）的化合物，可用于治疗病毒感染或作为免疫抑制剂。
• Sanglifehrin Based Compounds
  申请人：Moss Steven James

  公开号：US20120295841A1

  公开（公告）日：2012-11-22

  There are provided inter alia compounds of formula (I) useful as cyclophilin inhibitors.
• ANTIMICROBIAL COMPOUNDS, COMPOSITIONS, AND USES THEREOF
  申请人：Lakewood Amedex, Inc.

  公开号：US20210139522A1

  公开（公告）日：2021-05-13

  Antimicrobial compounds and compositions of Formulas (I) to (III) and methods of use are disclosed. Another aspect of the present disclosure provides a pharmaceutical composition comprising a compound according to Formula (I) to (III), or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, excipients, or diluents. Another aspect of the present disclosure provides a method of treating a bacterial infection in a patient in need thereof, the method of comprising administering an effective amount of a compound according to Formula (I) to (III), or a pharmaceutically acceptable salt thereof, to the patient.
• US9139613B2
  申请人：——

  公开号：US9139613B2

  公开（公告）日：2015-09-22